Abstract: The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.

Abstract: Device comprising a high brightness broad-area edge-emitting semiconductor laser and method of making the same. The device includes an edge-emitting semiconductor laser, said laser having a multi-layered waveguide, and said waveguide comprising at least one layer with an active region that emits light under electrical injection, and at least one aperiodic layer stack.

Abstract: A method for producing a polyglycerol nanogel is disclosed, the method comprising the following steps: Mixing an aqueous solution of first polyglycerol macromonomers, which are modified with a first reactive group, with an aqueous solution of second polyglycerol macromonomers, which are modified with a second reactive group, wherein the first reactive group and the second reactive group can react with each other forming a chemical bond; transferring the mixture into an organic non-solvent; and precipitation of a polyglycerol nanogel consisting of first polyglycerol macromonomers and second polyglycerol macromonomers which are covalently bound to each other. According to an aspect of the invention, the method is characterized in that the organic non-solvent is miscible with water and in that the method is carried out without adding surface-active substances.

Abstract: The present invention relates to a method for preparation of a 2-chloro-1,10-phenanthrolinamine, comprising the steps: i) conversion of a 2-chloro-1,10-phenanthroline to a 2-chloro-nitro-1,10-phenanthroline characterized by a formula 2, j) hydrogenation of said 2-chloro-nitro-1,10-phenanthroline characterized by formula 5 to a 2-chloro-1,10-phenanthrolinaminecharacterized by formula 3. The present invention relates further to a method for preparation of a 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[carboxymethyl-[2-[4-[2-(isothiocyanato-1,10-phenanthrolin-2-yl)ethynyl]anilino]-2-oxo-ethyl]amino]ethyl]amino]acetic acidcharacterized by formula 7 and a method for quantifying a biomolecule in a sample.

Abstract: The invention relates to methods for diagnosing bone disorders and/or cardiovascular disorders in a subject, by contacting a biological sample from the subject with (a) a nucleic acid molecule which hybridizes to miR-31 or its 5 or 3? isoforms or variants, or (b) an agent that binds to miR-31 or its 5? or 3? isoforms or variants; detecting and evaluating the hybridization signal of the nucleic acid molecule or agent with a polynucleotide or said miR-31 or its 5? or 3? isoforms or variants; and comparing the detected and evaluated hybridization or binding signal with that of a control sample, wherein a stronger hybridization signal or a stronger binding signal in the sample of the subject compared to that of the control sample is indicative for a risk of developing or having a bone disorder and/or cardiovascular disorder.

Abstract: The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilization as bioanalytical tags for biomolecules.

Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.

Abstract: The present invention comprises a process to synthesise metal complexes from macrocyclic polyazapyridinophane compounds characterised as superoxide dismutase enzyme (SOD) mimetics. Furthermore, the present invention relates to the macrocyclic polyazapyridinophane compounds themselves, the metal complexes formed from these and to their use in the treatment of diseases the aetiology of which is based on disturbances in the activity of, or a deficiency in endogenous SOD, mainly as anti-inflammatories, analgesics and antioxidant compounds providing protection against cellular oxidative stress.

Abstract: The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Abstract: The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the viral genome in infected cells that allows promotion of the affected cells to precancerous and cancerous cells. The invention therefore provides methods of diagnosing neoplasias and their precursor lesions as well as methods of preventing the development of malignancies or inhibiting tumor growth.

Abstract: To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an Integer from 1 to 3 and n is an integer from 1 to 6.

Abstract: A circuit for activating a capacitive MEMS structure is provided, with the capacitive MEMS structure having an oscillator element and an electrostatic excitation unit with a first input connection and a second input connection. The circuit includes a high voltage generator, a first pump capacitor, a second pump capacitor, a control unit, and a low voltage operation amplifier. The high voltage generator generates a high voltage and connects to the first input connection and the second input connection. The first pump capacitor is connected to the high voltage generator and includes a first connection connected to the first input connection. The second pump capacitor connects to the high voltage generator and includes a first connection connected to the second input connection. The control unit connects to a second connection of the first pump capacitor and a second connection of the second pump capacitor. The low voltage operation amplifier connects to the control unit.

Abstract: The present invention relates to non-competitive allosteric peptide inhibitors of DPP9 and/or DPP8, competitive peptides binding to SUMO1, nucleic acid molecules and expression vectors coding said peptide inhibitors, host cells expressing said inhibitors, kits comprising said inhibitors, as well as methods of producing said inhibitors, and uses of said peptide inhibitors; as further defined in the Claims.

Abstract: System for preventing bacterial infections in needle trajectories. The system includes a percutaneous surgical instrument (1) percutaneously introducible into a patient's tissue (3) such as a biopsy needle, and having an outer surface made of an electrically conductive material; a contact electrode (4) applicable to the patient's skin (3a); a silver coating or element (P) arranged on or forming part of the instrument (1) to break down by electrochemical release when a current is applied thereto, releasing silver ions into its surroundings; and an electric current generator (2) arranged and configured for generating a current and inducing the temporary circulation thereof between the instrument (1) acting as an anode, the tissue (3) and the contact electrode (4) acting as a cathode, respectively, with a specific magnitude and duration for producing a massive and sudden release of silver ions for the purpose of preventing post-treatment bacterial infections.

Abstract: The invention relates to novel strategies for the treatment of cancer patients based on a combination of an opioid receptor agonist and an anticancer compound.

Abstract: The present invention relates to a method of production of plants having improved resistance to low-temperature stress, comprising a stage of conversion of the cells of a plant with a sequence of exogenous arginine decarboxylase gene ADC1 under control of a promoter capable of functioning in the plant. Plants thus obtained show resistance to low-temperature stress without the phenotype being affected when compared with the phenotype of plants of the wild type.

Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are—useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.

Abstract: The invention relates to a component for high-temperature applications, to a method for the production thereof and to a use thereof. In this respect, an electrical conductivity and a catalytic effect should be achievable with a simultaneous chemical and thermal resistance under different conditions and also at temperatures above 700° C. The component in accordance with the invention is formed from a body which is formed from Ce1-x-yLnxMeyO2. In this respect, Ln is a rare earth metal and Me is a transition metal, where x=0.01 to 0.25 and y=0.05 to 0.2. Particles having a mean particle size in the range from 5 nm to 500 nm, preferably in the range from 10 nm to 300 nm, and formed using transition metal, are present in a distributed arrangement on at least one surface.